RxDoctor Payments Data

Brandon Hecht, DO

Family Medicine · Boiling Springs, SCNPI 1578827713

Payments from drug & device makers

$2,216in general payments, 2019–2025

Across 108 payments — averaging $20.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$312
  • AstraZeneca$252
  • Lilly USA, LLC$217
  • Dexcom, Inc.$210
  • Pfizer$169
  • Abbott$156
  • plus $900 from 24 others

What the payments were for

  • Food & beverage$2,216100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,216 in reported general payments places this provider in the 70th percentile of 2,153 family medicine providers in South Carolina.

See all family medicine providers in South Carolina

Medicare billing

Part B allowed, 2024
$168,068
Medicare patients
752
Services billed
13,451

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide42$85,380
JardianceEmpagliflozin58$67,548
EliquisApixaban56$55,655
Repatha SureclickEvolocumab26$35,992
MounjaroTirzepatide18$34,334
FarxigaDapagliflozin Propanediol23$25,292
LinzessLinaclotide20$25,044
XareltoRivaroxaban22$21,008
Stiolto RespimatTiotropium Br/Olodaterol Hcl22$10,161
Bydureon BciseExenatide Microspheres11$9,658
EntrestoSacubitril/Valsartan15$8,767
Praluent PenAlirocumab18$8,720
Bevespi AerosphereGlycopyrrolate/Formoterol Fum17$7,692
CorlanorIvabradine Hcl12$7,038
Breo ElliptaFluticasone/Vilanterol15$6,524

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$312$85,38042 claims
PfizerEliquis$169$55,65556 claims
Lilly USA, LLCMounjaro$217$34,33418 claims
AstraZenecaFarxiga, Bevespi Aerosphere$252$32,98440 claims
AbbVieLinzess, Synthroid$113$26,74340 claims
Johnson & JohnsonXarelto$22$21,00822 claims
AmgenCorlanor$74$7,03812 claims
GSKBreo Ellipta$108$6,52415 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 2,153 family medicine providers in South Carolina.

Other family medicine in Boiling Springs

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →